Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
451
datasets available to search
ShareScore release 0.9.0
Dataset results
451 results for “AMD”
Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD
ClinicalTrials.gov study NCT02800356. IPD Sharing: UNDECIDED. Countries: 1. Publications: 8.
Carbidopa-levodopa in Neovascular AMD
ClinicalTrials.gov study NCT03022318. IPD Sharing: NO. Countries: 1. Publications: 8.
AMD 3100 for Treatment of Myelokathexis
ClinicalTrials.gov study NCT01058993. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
ClinicalTrials.gov study NCT03066258. IPD Sharing: NO. Countries: 1. Publications: 1.
12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT01362348. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Pilot Study of X-82 in Patients With Wet AMD
ClinicalTrials.gov study NCT01674569. IPD Sharing: NO. Countries: 1. Publications: 1.
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT00637377. IPD Sharing: Not stated. Countries: 26. Publications: 6.
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT00658619. IPD Sharing: Not stated. Countries: 7. Publications: 1.
Data from: Low incidence of choroidal neovascularization following subthreshold diode micropulse laser (SDM) in high-risk AMD
Purpose: To determine the incidence of new choroidal neovascularization (CNV) in eyes with dry age-related macular degeneration (AMD) following subthreshold diode micropulse laser (SDM). Method: In an observational retrospective cohort study, the records of all patients active in the electronic medical records database were reviewed to identify eyes with dry AMD treated with SDM. Identified eyes were classified by simplified AREDS categories, and analyzed for the primary endpoint of new CNV after treatment. Results: The EMR revealed SDM was offered to 373/392 (95%) patients with dry AMD and elected by 363/373 (97%) between 2008-2017. Follow up was available for 354/363 patients (547 eyes, 98%) (range 6-108 mos., avg. 22). CNV risk factors included age (median 84 years, 67% > 80); reticular pseudodrusen (214 eyes, 39%); AREDS category (78% category 3 and 4); and fellow eye CNV (128 eyes, 23%). New CNV developed in 9/547 eyes (1.6%, annualized rate 0.87%). Visual acuity was unchanged. There were no adverse treatment effects. Summary: In a review of a large group of eyes with exceptionally high-risk AMD, SDM was followed by a very low incidence of new CNV. If confirmed by further study, SDM would offer a new and highly effective treatment to reduce the risk of vision loss from AMD.
All-atom accelerated molecular dynamics (aMD) simulations of Filamin-A (FLNa) actin-binding Domain, immunoglobulin-like Domains 3, 4, 5, 21 and 24 to investagate the impact of known missense mutations associated with periventricular nodular heterotopia in the liveborn males
<p>Data includes all of the wild-type and mutant trajectories of accelerated all-atom molecular dynamics (aMD) simulations of Filamin-A (FLNa, the product of <em>FLNA</em> gene located on chromosome X). Wild-type proteins are from the PDB structures with IDs: 4M9P, 3HOP, 3CNK. The mutations, including R484Q that we discovered in a Turkish family, were formerly found in the liveborn males with <em>FLNA</em>-associated periventricular nodular heterotopia (PNH), who survived with the only copy of mutated <em>FLNA</em>. To understand how these mutations lead to the PNH and simultaneously allow their survival, we performed these MD simulations for the wild-type and mutant systems.</p> <p>Systems were prepared in Visual Molecular Dynamics (VMD 1.9.3) by placing them in a TIP3P water box with approximately 20 Å thickness from the protein surface and neutralizing the system by adding counter ions in the form of NaCl. Of note, only protein parts were kept for the submission to reduce the size of files. Nanoscale Molecular Dynamics (NAMD 2.13-CUDA) was used to perform MD simulations with CHARMM36m force field. For pressure and temperature controls, Nosé-Hoover Langevin barostat and Langevin thermostat were used. ShakeH algorithm of NAMD was applied for water molecule constraints. 12 Å cut-off distance was used for van der Waals interactions. Switching function starts at 10 Å and reaches zero at 14 Å. Integration time-step was 2 fs. To compute the long-range Coulomb interactions, the particle-mash Ewald method was used. After a 10000-step minimization with conjugate gradient algorithm and an equilibration for 1 ns at 298 K under NVT ensemble, production simulations were run along 100 ns. Only the production simulations were supplied in this dataset. Further details are available in the regarding configuration files.</p> <p>Resulting analysis files and scripts are included with the carbon alpha-containing dcd files of the simulations.</p> <p>This dataset is not used directly for any study, but they are preliminary results for the usage of aMD to understand rare disease mechanisms.</p> <p>Related publications:</p> <pre>Zenodo repo of classical MD for these variants: https://doi.org/10.5281/zenodo.4483108</pre> <p>Journal article based on classical MD:</p> <p>Gerlevik U, Saygı C, Cangül H, Kutlu A, Çaralan EF, Topçu Y, et al. (2022) Computational analysis of missense filamin-A variants, including the novel p.Arg484Gln variant of two brothers with periventricular nodular heterotopia. PLoS ONE 17(5): e0265400. https://doi.org/10.1371/journal.pone.0265400</p>
Wenzhou Dry Age-related Macular Degeneration (AMD) Progression Study
ClinicalTrials.gov study NCT03433885. IPD Sharing: Not stated. Countries: 1. Publications: 11.
Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT03946085. IPD Sharing: YES. Countries: 1. Publications: 1.
The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT02438111. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Treatment of AMD With Rheohemapheresis /RHF/
ClinicalTrials.gov study NCT01943396. IPD Sharing: Not stated. Countries: 1. Publications: 11.
Age-related Macular Degeneration (AMD) and Cardiovascular Disease
ClinicalTrials.gov study NCT04087356. IPD Sharing: NO. Countries: 1. Publications: 1.
The Optical Coherence Tomography in Age-Related Macular Degeneration Study: The OCT in AMD Study
ClinicalTrials.gov study NCT00531141. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
ClinicalTrials.gov study NCT05893537. IPD Sharing: NO. Countries: 1. Publications: 0.
MMP-9 Inhibition for Recalcitrant Wet AMD
ClinicalTrials.gov study NCT04504123. IPD Sharing: NO. Countries: 1. Publications: 69.
Comparison of Cytokine Profiles in Aqueous Humor of Patients With Age Related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT03418220. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD
ClinicalTrials.gov study NCT05678517. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.